SciELO - Scientific Electronic Library Online

 
vol.47 issue1Translating basic research in cancer patient careThe role of the Istituto Superiore di Sanità as the competent authority for Phase I trials in the translation of advanced therapies author indexsubject indexarticles search
Home Page  

Annali dell'Istituto Superiore di Sanità

Print version ISSN 0021-2571

Abstract

BELARDELLI, Filippo et al. Translational research on advanced therapies. Ann. Ist. Super. Sanità [online]. 2011, vol.47, n.1, pp. 72-78. ISSN 0021-2571.  http://dx.doi.org/10.4415/ANN_11_01_15.

Fostering translational research of advanced therapies has become a major priority of both scientific community and national governments. Advanced therapy medicinal products (ATMP) are a new medicinal product category comprising gene therapy and cell-based medicinal products as well as tissue engineered medicinal products. ATMP development opens novel avenues for therapeutic approaches in numerous diseases, including cancer and neurodegenerative and cardiovascular diseases. However, there are important bottlenecks for their development due to the complexity of the regulatory framework, the high costs and the needs for good manufacturing practice (GMP) facilities and new end-points for clinical experimentation. Thus, a strategic cooperation between different stakeholders (academia, industry and experts in regulatory issues) is strongly needed. Recently, a great importance has been given to research infrastructures dedicated to foster translational medicine of advanced therapies. Some ongoing European initiatives in this field are presented and their potential impact is discussed.

Keywords : translational research; advanced therapy medicinal products; research infrastructures.

        · abstract in Italian     · text in English     · pdf in English